• Monitor disease in patient previously diagnosed with pemphigoid and increased antibodies for IgG BP 180 and/or BP 230; IgG BP 180 antibody levels correlate with disease activity.
• For initial diagnosis and assessment of disease progression or changes, the preferred test is Basement Membrane Zone Antibody Panel (3001410), or Immunobullous Disease Panel, Epithelial (3001409).
• Epithelial Basement Membrane Zone Antibody IgG (0092056) can be used to determine the involvement of IgG BMZ antibodies and pattern of reactivity on split skin substrate. Also consider other types of BMZ antibody-associated disease testing, (ie, Epithelial Basement Membrane Zone Antibody IgA (0092057), Collagen Type VII Antibody IgG by ELISA (2010905), or Herpes Gestationis Factor (Complement-Fixing Basement Membrane Zone Antibody IgG) (0092283)).
Enzyme-Linked Immunosorbent Assay
Plain red or serum separator tube (SST).
Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Hemolyzed or lipemic specimens.
Ambient: 1 week; Refrigerated: 2 weeks; Frozen: Indefinitely
No compliance statements are in use for this test.
For specimens less than 0.5 mL, call the Immunodermatology Laboratory at (866) 266-5699.
|Component Test Code*||Component Chart Name||LOINC|
|0092568||Bullous Pemphigoid Antigens, IgG||57911-0|
|2010915||EER Bullous Pemphigoid Antigens, IgG|
- BP 180 and BP 230
- BP Antigen 1
- BP Antigen 2